Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone

Brain Research

Volumn 1231, Issue , 2008, Pages 16-24

  Crain, Stanley M ^a   Shen, Ke Fei ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclic AMP phosphodiesterase inhibitor; Endogenous opioid analgesia; Endogenous opioid hyperalgesia; Excitatory Gs coupled opioid receptor; Kelatorphan; Ultra low dose naltrexone

Indexed keywords

BETA FUNALTREXAMINE; CAFFEINE; CHOLERA TOXIN B SUBUNIT; CYCLIC AMP PHOSPHODIESTERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOBUTYLMETHYLXANTHINE; KELATORPHAN; NALTREXONE; NORBINALTORPHIMINE; OPIATE RECEPTOR; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HYPERALGESIA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TEMPERATURE SENSITIVITY;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANALGESIA; ANALGESICS; ANIMALS; CYCLIC AMP; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPERALGESIA; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTORS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; TIME FACTORS;

MUS;

EID: 50649107928     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.07.015     Document Type: Article

References (63)

1. Abul-Husn N.S., Sutak M., Milne B., and Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ- and δ-opioid receptor antagonists. Br. J. Pharmacol. 151 (2007) 877-887
2. Arnold M.A., Carr D.B., Togasaki D.M., Pian M.C., and Martin J.B. Caffeine stimulates β-endorphin release in blood but not in cerebrospinal fluid. Life Sci. 31 (1982) 1017-1024
3. Bach M.E., Barad M., Son H., Zhuo M., Lu Y.-F., Shih R., Mansuy I., Hawkins R.D., and Kandel E.R. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 5280-5285
4. Barad M., Bourtchouladze R., Winder D.G., Golan H., and Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15020-15025
5. Basbaum A.I., Cruz L., and Weber E. Immunoreactive dynorphin B in sacral primary afferent fibers of the cat. J. Neurosci. 6 (1986) 127-133
6. Bloom F., Segal D., Lin N., and Guillemin R. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194 (1976) 630-632
7. Cheng H.Y.-M., Pitcher G.M., Laviolette S.R., Whishaw I.Q., Tong K.I., Kockeritz L.K., Wada T., Joza N.A., Crackower M., Goncalves J., Sarosi I., Woodgett J.R., Oliveira-dos-Santos A.J., Ikura M., van der Kooy D., Salter M.W., and Penninger J.M. DREAM is a critical transcriptional repressor for pain modulation. Cell 108 (2002) 31-43
8. Chindalore V.L., Craven R.A., Yu P., Butera P.G., Burns L.H., and Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex. J. Pain 6 (2005) 392-399
9. Collier H.O.J., Francis D.L., Henderson G., and Schneider C. Quasi-morphine-abstinence syndrome. Nature 249 (1974) 471-473
10. Collier H.O.J., Cuthbert N.J., and Francis D.L. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines. FASEB 40 (1981) 1513-1518
11. Crain S.M., and Shen K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11 (1990) 77-81
12. Crain S.M., and Shen K.-F. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res. 575 (1992) 13-24
13. Crain S.M., and Shen K.-F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10540-10544
14. Crain S.M., and Shen K.-F. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol. Sci. 19 (1998) 358-365
15. Crain S.M., and Shen K.-F. GM1 ganglioside-induced modulation of opioid receptor-mediated functions. Ann. N. Y. Acad. Sci. 845 (1998) 106-125
16. Crain S.M., and Shen K.-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84 (2000) 121-131
17. Crain S.M., and Shen K.-F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 888 (2001) 75-82
18. Crain S.M., and Shen K.-F. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res. 995 (2004) 260-266
19. Crain S.M., and Shen K.-F. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naive mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice. Brain Res. 1167 (2007) 31-41
20. Crain S.M., Crain B., and Peterson E.R. Cyclic AMP or forskolin rapidly attenuates the depressant effects of opioids on sensory-evoked dorsal-horn responses in mouse spinal cord-ganglion explants. Brain Res. 370 (1986) 61-72
21. Cruciani R.A., Lussier D., Miller-Saultz D., and Arbuck D.M. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J. Pain Symptom Manag. 25 (2003) 491-494
22. Cunha F.Q., Teixera M.M., and Ferreira S.H. Pharmacological modulation of secondary mediator systems-cyclic AMP and cyclic GMP-on inflammatory hyperalgesia. Br. J. Pharmacol. 127 (1999) 671-678
23. 5]enkephalin and dynorphin A in rat spinal cord. Chin. Sci. Bull. 32 (1987) 1496-1501
24. ++ dependent process. Prostaglandins 18 (1979) 179-190
25. Fournie-Zaluski M.C., Chaillet P., Bouboutou R., Coulaud A., Cherot P., Waksman G., Costentin J., and Roques B.P. Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol. 102 (1984) 525-528
26. Han J.S., and Xie C.W. Dynorphin: potent mediator for electroacupuncture analgesia in spinal cord of the rabbit. Pain 40 (1984) 367-376
27. Ho I.K., Loh H.H., and Way E.L. Cyclic adenosine monophosphate antagonism of morphine analgesia. J. Pharmacol. Exp. Ther. 185 (1973) 336-346
28. Hosford D.A., and Haigler H.J. Cyclic AMP, morphine, Met-enkephalin and neuronal firing. J. Pharmacol. Exp. Ther. 219 (1981) 496-504
29. Houslay M.D., Schafer P., and Zhang K.Y.J. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10 (2005) 1503-1519
30. Jurna I. Cyclic nucleotides and aminophylline produce different effects on nociceptive motor and sensory responses in the rat spinal cord. Naunyn-Schmiedeberg's Arch. Pharmacol. 327 (1984) 23-30
31. Kayser V., Fournie-Zaluski M.C., Guilbaud G., and Roques B.P. Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin degrading enzymes) systemically administered in normal and arthritic rats. Brain Res. 497 (1989) 94-101
32. Krause W., Kuhne G., and Sauerbrey N. Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers. Eur. J. Clin. Pharmacol. 38 (1990) 71-75
33. 2 antagonist or methadone. Pain 104 (2003) 139-148
34. Loh H.H., Tseng L.F., Wei E., and Li C.H. β-Endorphin is a potent analgesic agent. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 2895-2898
35. Noble F., and Roques B.P. Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin. Ther. Targets 11 (2007) 145-159
36. 2-induced mechanical hyperalgesia in the rat. Neuroscience 64 (1995) 769-776
37. Powell K.J., Abul-Husn N.S., Jhamandas A., Olmstead M.C., Beninger R.J., and Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J. Pharmacol. Exp. Ther. 300 (2002) 588-596
38. Roques B.P. Novel approaches to targeting neuropeptide systems. Trends Pharmacol. Sci. 21 (2000) 475-483
39. Roques B.P., and Noble F. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. In: Rapaka R.S., and Sorer H. (Eds). Discovery of Novel Opioid Medications. Vol. 147 (1995), NIDA Research Monograph 104-145
40. Roques B.P., Noble F., and Fournie-Zaluski M.C. Endogenous opioid peptides and analgesia. In: Stein C. (Ed). Opioids in Pain Control (1999), Cambridge Univ. Press, Cambridge 21-45
41. Schaible H.G. Peripheral and central mechanisms of pain generation. Handb. Exp. Pharmacol. 177 (2007) 3-28
42. Scheideler M.A., and Dawson G. Direct demonstration of the activation of UDP-N-acetylgalactosamine:[GM3]N-acetylgalactosaminyltransferase by cyclic AMP. J. Neurochem. 4 (1986) 1639-1643
43. Shen K.-F., and Crain S.M. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 491 (1989) 227-242
44. Shen K.-F., and Crain S.M. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Res. 525 (1990) 225-231
45. Shen K.-F., and Crain S.M. Cholera toxin-B subunit blocks opioid excitatory effects on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res. 531 (1990) 1-7
46. Shen K.-F., and Crain S.M. Nerve growth factor rapidly prolongs the action potential of mature sensory neurons in culture and this effect requires activation of Gs-coupled excitatory kappa opioid receptors on these cells. J. Neurosci. 14 (1994) 5570-5579
47. Shen K.-F., and Crain S.M. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 757 (1997) 176-190
48. Shen K.-F., and Crain S.M. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain Res. 919 (2001) 20-30
49. Sloan P., and Hamann S. Ultra-low-dose opioid antagonists to enhance opioid analgesia. J. Opioid Manag. 2 (2006) 295-304
50. Sluka K.A. Activation of the cAMP transduction cascade contributes to the mechanical hyperalgesia and allodynia induced by intradermal injection of capsaicin. Br. J. Pharmacol. 122 (1997) 1165-1173
51. Suarez-Roca H., and Maixner W. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. J. Pharmacol. Exp. Ther. 264 (1993) 648-653
52. Suarez-Roca H., and Maixner W. Morphine produces a biphasic modulation of substance P release from cultured dorsal root ganglion neurons. Neurosci. Lett. 194 (1995) 41-44
53. Taiwo Y.O., and Levine J.D. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 44 (1991) 131-135
54. Taiwo Y.O., Bjerknes L.K., Coetzl E.J., and Levine J.D. Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 32 (1989) 577-580
55. Tallarida R.J., and Murray R.B. Manual of Pharmacologic Calculation With Computer Programs. 2nd Ed. (1987), Springer-Verlag, New York
56. Teixeira M.M., Gristwood R.W., Cooper N., and Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. Trends Pharmacol. Sci. 18 (1997) 164-167
57. Tsai, R.Y., Jang, F.L., Tai, Y.H., Lin, S.L., Shen, C.H., Wong, C.S., in press. Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats. Neuropsychopharmacology.
58. Tseng L.F. Mechanisms of β-endorphin-induced antinociception. In: Tseng L.F. (Ed). The Pharmacology of Opioid Peptides (1995), Harwood Academia Publishers, United States 249-269
59. Waldhoer M., Bartlett S.E., and Whistler J.L. Opioid receptors. Annu. Rev. Biochem. 73 (2004) 953-990
60. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., Hruby V.J., Malan T.P., Lai J., and Porreca F. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. 21 (2001) 1779-1786
61. Wang H.-Y., Friedman E., Olmstead M.C., and Burns L.H. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbg signaling. Neuroscience 135 (2005) 247-261
62. Wu G., Lu Z.-H., and Ledeen R.W. Interaction of δ-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode. Mol. Brain Res. 44 (1997) 341-346
63. Wu G., Lu Z.-H., Tzongjer J.W., Howells R.D., Christoffers K., and Ledeen R.W. The role of GM1 ganglioside in regulating excitatory opioid effects. Ann. N. Y. Acad. Sci. 845 (1998) 126-138